In recent years, the relevance of Lab-on-Chip (LOC) technology and micro-Total-Analysis-Systems (mTAS) has developed in tandem with the growing demand to carry out diagnostic procedures outside of a laboratory setting. This has resulted in the expansion of the potential for these two types of systems. The consolidation of several laboratory procedures onto a single device has become significantly easier because of recent developments in micro- and nanofabrication. TAS takes these capabilities to a whole new level by including incorporating chemical analysis with the intention of developing platforms that function as "Sample-In, Answer-Out" systems. The diagnosis and monitoring of patients may be moved from traditional clinical treatment settings to the patient's bedside using point-of-care (POC) environments, which can make use of the aforementioned technologies to great effect. Digital microfluidics biochips, also known as DMFB, are a relatively new LOC technology that is increasingly being investigated as a potential platform for use in point-of-care field deployment and in the process of providing a prompt diagnosis. Processing mistakes are a natural consequence of using a system like this.
This work is licensed under a Creative Commons Attribution 4.0 International License.
You may also start an advanced similarity search for this article.